Advancing Worsening Heart Failure Treatment: Exploring Cutting-Edge Therapies and Addressing Disparities



Director of Mount Sinai Heart; Dr. Valentin Fuster Professor of Cardiovascular Medicine
Icahn School of Medicine at Mount Sinai
New York, NY

Erin Michos, MD, MHS

Director of Women Cardiovascular Health Research
Associate Director of Preventive Cardiology at Johns Hopkins University School of Medicine
Co-Director, IMPACT Center at Johns Hopkins University
Co-Editor in Chief, American Journal of Preventive Cardiology
Baltimore, MD

Program Overview

HFrEF is a progressive and complex condition with very high rates of mortality and hospitalizations. Recently, positive cardiovascular (CV) outcomes and reduced hospitalization for heart failure (HF) were noted in patients with HF with reduced ejection fraction (HFrEF) treated with novel emerging agents. The inclusion of the soluble guanylate cyclase (sGC) stimulator, vericiguat; and the sodium-glucose cotransporter-2 (SGLT2), empagliflozin and dapagliflozin; have revolutionized the treatment of patients with HFrEF. The treatment of HFrEF requires one or more drugs from several classes, as recommended in the guidelines. Many factors need to be considered when selecting therapy for these patients, including how to initiate, add, or switch therapies, and how to assess the effectiveness of these treatments using imaging and biomarkers. Recent additions to guidelines including SGLT2 inhibitors and vericiguat have the potential to significantly decrease risk for hospitalization for patients with HFrEF. Timely implementation of these therapies is critical to achieve the anticipated health benefits.

Target Audience

This educational initiative is designed for cardiologists, preventive cardiologists, emergency department (ED) physicians, and all clinicians interested in managing patients with heart failure.

Podcasts Episodes

Med Ed Threads

This activity is jointly provided by Global Education Group and Iridium Continuing Education.
This activity is supported by an independent educational grant from
Merck, Sharpe, and Dohme, LLC.